Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Non-Small-Cell Lung Cancer (RTOG 3505)

David E. Gerber, University of Texas
James J. Urbanic, University of California San Diego
Corey Langer, University of Pennsylvania
Chen Hu, Johns Hopkins University
I-Fen Chang, Bristol-Myers Squibb
Bo Lu, Thomas Jefferson University
Benjamin Movsas, Henry Ford Hospital
Robert Jeraj, University of Wisconsin
Walter J Curran, Emory University
Jeffrey D. Bradley, Washington University

Journal Title: Clinical Lung Cancer
Volume: Volume 18, Number 3
Publisher: Elsevier: 12 months | 2017-05-01, Pages 333-339
Type of Work: Article | Post-print: After Peer Review
Publisher DOI: 10.1016/j.cllc.2016.10.009
Permanent URL: https://pid.emory.edu/ark:/25593/s9nhf

Final published version: http://dx.doi.org/10.1016/j.cllc.2016.10.009

Copyright information:
© 2016 Elsevier Inc.
This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Treatment design and rationale for a randomized trial of cisplatin and etoposide plus thoracic radiation therapy followed by nivolumab or placebo for locally advanced non-small cell lung cancer (RTOG 3505)

David E. Gerber¹, James J. Urbanic², Corey Langer³, Chen Hu⁴,⁵, I-Fen Chang⁶, Bo Lu⁷, Benjamin Movsas⁸, Robert Jeraj⁹, Walter J. Curran¹⁰, and Jeffrey D. Bradley¹¹

¹Harold C. Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center
²University of California San Diego
³University of Pennsylvania
⁴Johns Hopkins University
⁵RTOG Foundation
⁶Bristol-Myers Squibb
⁷Thomas Jefferson University
⁸Henry Ford Hospital
⁹University of Wisconsin Carbone Cancer Center
¹⁰Emory University Medical Center
¹¹Washington University School of Medicine

Abstract

RTOG 3505 is a randomized phase 3 study of concurrent chemoradiation followed by immune checkpoint inhibitor therapy or placebo in patients with locally advanced non-small cell lung cancer (NSCLC). Patients with surgically unresectable stage 3 NSCLC will receive thoracic radiation therapy (RT) to 60 Gy with concurrent cisplatin 50 mg/m² IV on Days 1, 8, 29, and 36, and etoposide 50 mg/m² IV on Days 1–5 and 29–33. Between 4 and 12 weeks after completion of concurrent chemoradiation, eligible patients will be randomized to the anti-programmed death 1 (PD1) monoclonal antibody nivolumab 240 mg IV or placebo every 2 weeks for up to 1 year. Co-primary endpoints are overall survival (OS) and progression-free survival (PFS), as determined by
central independent radiology review. Secondary objectives include toxicity assessment, patient-reported outcomes and quality of life, and OS and PFS in PD-L1-expressors (≥1%) and PD-L1-non-expressors (<1%). Assuming a rate of 16.7% due to ineligibility and drop-out before randomization, a total of 660 patients will be enrolled to ensure 550 patients will be randomized after completion of chemoradiation. This sample size will provide ≥90% power to detect (1) a hazard ratio (HR) of 0.7 for OS with two-sided type I error of 0.04, and (2) HR of 0.667 for PFS two-sided type I error of 0.01. NCT02768558

Keywords
Abscopal effect; checkpoint inhibitor; co-primary endpoints; immunotherapy; programmed death 1 (PD1)

Study Rationale

We have reached a plateau in outcomes for locally advanced non-small cell lung cancer (NSCLC). Despite aggressive therapy with concurrent chemoradiation, fewer than 20–25% of patients with stage 3 NSCLC achieve 5-year survival and are presumably cured. To date, modifications of chemotherapy have not improved these outcomes. The addition of 3 cycles of consolidation docetaxel after concurrent cisplatin-etoposide with thoracic radiation has no impact on overall survival compared to chemoradiation alone.\(^1\) There is no survival advantage for consolidative docetaxel/cisplatin after definitive chemoradiation compared to chemoradiation alone.\(^2\) In unselected patients with stage 3 NSCLC, the addition of the epidermal growth factor receptor inhibitor gefitinib as maintenance therapy after completion of cisplatin-based concurrent chemoradiation demonstrates a decrease in survival.\(^3\) Adding the anti-EGFR monoclonal antibody cetuximab to chemoradiation does not extend survival.\(^4\) Furthermore, there is no evidence that achievable radiation therapy (RT) doses above 60 Gy are better than 60 Gy. In an interim analysis of the Radiation Therapy Oncology Group (RTOG) 0617 clinical trial, patients receiving an RT dose of 74 Gy had a median progression-free survival of 9.8 months, compared to 11.8 months for patients receiving 60 Gy.\(^4\)

There is a strong rationale to combine immunotherapy and RT. While NSCLC is typically considered relatively non-immunogenic, RT may augment tumor immunogenicity.\(^5\) The *abscopal effect* refers to the observation that RT to a local area results in an antitumor effect distant to the radiation site. One proposed mechanism for this phenomenon is induction of release of circulating tumor antigen or inflammatory factors that could then mediate an augmented immune response against distant malignant lesions expressing similar tumor antigens. Supporting this hypothesis, local RT has been shown to increase the activity of natural killer cells, and T cells are required to mediate distant tumor effects of radiotherapy.\(^6,7\) Ablative RT dramatically increases T-cell priming in draining lymphoid tissues, leading to reduction of the primary tumor or distant metastases in a CD8+ T-cell-dependent fashion. These RT-initiated immune responses were greatly amplified by local immunotherapy.\(^8\) Finally, RT has been shown to increase tumor expression of programmed death ligand 1 (PD-L1), with combined RT plus PD-1-pathway targeting resulting in
synergistic suppression of tumor-infiltrating myeloid-derived suppressor cells (MDSCs), thereby promoting anti-tumor immunity. With the availability of immune checkpoint inhibitors such as the anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody, ipilimumab, and agents targeting the PD-1 pathway, the potential benefit of combining these agents with RT has become evident clinically. Case reports suggest the induction of abscopal effect with administration of these agents. Among cancer types, lung cancer may be a particularly attractive setting to incorporate immunotherapy into treatment paradigms. A number of studies have suggested that tumor mutational burden is associated with benefit from immunotherapy. Presumably, increased mutational burden results in increased tumor antigenicity, thereby priming the tumor for immune attack. Lung cancer carries one of the highest mutational burdens of any malignancy, second only to melanoma. With two anti-PD1 agents already established and approved in advanced NSCLC, there is clear rationale to explore in earlier stages and in novel combinations.

In contrast to CTLA-4 (which exerts its regulatory effects in the priming phase of the immune response in regional lymph nodes), the negative regulatory effects of the PD-1 pathway occur in the effector phase of the immune response in peripheral tissues. Following T-cell stimulation, PD-1 recruits the tyrosine phosphatases SHP-1 and SHP-2, resulting in dephosphorylation of multiple effector molecules involved in the CD3 T-cell signaling cascade. Nivolumab (BMS-936558, previously MDX-1106 and ONO-4538), an anti-PD-1 monoclonal antibody, has emerged as one of the most promising immunotherapies for lung cancer. Nivolumab is a fully human, IgG4 (kappa) monoclonal antibody that binds PD-1 on activated immune cells to disrupt engagement of receptor with ligands PD-L1 (B7-H1/CD274) and PD-L2 (B7-DC/CD273). This action results in counteracting inhibitory signals and augmenting host antitumor responses. In early clinical trials, nivolumab monotherapy demonstrated clinical activity in multiple tumor types, including melanoma, renal cell carcinoma, and NSCLC. In a multicenter phase I dose-escalation trial enrolling NSCLC, melanoma, renal cell carcinoma, castration-resistant prostate cancer, and colorectal cancer, radiographic response rate in advanced, previously treated NSCLC was 17% (22 of 129 patients). Among the 22 patients with objective responses, the Kaplan-Meier estimated median duration of response was 17.0 months.

Two phase 3 clinical trials (Checkmate 057 and Checkmate 017) comparing nivolumab to single-agent docetaxel chemotherapy in previously treated advanced NSCLC have demonstrated improved overall survival and improved tolerability with nivolumab compared to docetaxel, leading to U.S. FDA approval and category 1 recommendations by the National Comprehensive Cancer Network. Both trials have demonstrated improved overall survival with nivolumab compared to docetaxel. The Checkmate 057 trial enrolled patients with nonsquamous NSCLC. In the unselected population, for patients receiving nivolumab, median overall survival (OS) was 12.2 months compared with 9.4 months for docetaxel (HR 0.73, HR 0.59–0.89, P=0.002). Fewer grade 3 to 5 adverse events were reported for nivolumab (10%) when compared with docetaxel (54%). Clinical benefit was particularly evident for patients whose tumors had PD L1 staining of 1% or more (HR 0.59). There did not appear to be a survival benefit for nivolumab over docetaxel in the PDL1-negative population (HR)}
0.9), although duration of response was substantially longer and tolerability was better in the nivolumab arm. Nivolumab-related select adverse events observed included infusion-related reactions (3%; no grade 3–4), rash (9%; <1% grade 3–4), pneumonitis (3%; 1% grade 3–4), ALT/AST increased (3%; <1% grade 3–4), diarrhea (8%; 1% grade 3–4), and hypothyroidism (7%; no grade 3–4). Checkmate 017 enrolled patients with squamous NSCLC. Compared to docetaxel, nivolumab resulted in a 41% reduction in the risk of death (HR 0.59; 95% CI, 0.44–0.79; P<0.001). Median OS was 9.2 months in the nivolumab arm (95% CI, 7.3–13.3 months) and 6 months in the docetaxel arm (95% CI, 5.1–7.3 months). Toxicity rates were similar to those in Checkmate 057. Although Checkmate 026 did not demonstrate superior PFS or OS of nivolumab over platinum doublet chemotherapy in previously untreated advanced NSCLC with ≥5% cells PD-L1 positive, there may still be benefit of nivolumab monotherapy when administered after chemoradiation, a clinical scenario in which observation is the current standard of care.

Due to potential overlapping pneumonitis with radiation therapy, nivolumab pulmonary toxicity is a particular concern in the setting of locally advanced NSCLC. To date, across the clinical trial experience in 2,166 patients with solid tumors, fatal immune-mediated pneumonitis has occurred in 0.2% (5/2166) of patients receiving nivolumab. All five fatal cases occurred early in the nivolumab development program. Perhaps reflecting cumulative experience with and knowledge of this potential toxicity, there were no fatal cases of pneumonitis in the phase 3 Checkmate 017 and Checkmate 057 trials. In Checkmate 017, pneumonitis occurred in 5% of patients receiving nivolumab, of which there was only one Grade 3 case and no Grade 4 cases. The median time to onset of treatment-related pulmonary events was 15.1 weeks (range, 2.6 to 85.1 weeks). All cases resolved upon discontinuation of nivolumab and administration of corticosteroids, with median time to resolution of 5.0 weeks (range 0.6 to 12.1 weeks). In Checkmate 057, any grade pneumonitis was 3% and grade 3 and above pneumonitis was 1%. The low rate of pneumonitis and the good response to supportive therapy seen in the most recent nivolumab trials suggests that, with appropriate monitoring and precautions, this agent could be studied in combination with thoracic radiation therapy.

Although nivolumab has not yet been studied in combination with RT, data are available for nivolumab-treated patients who previously received RT. While the precise timing and nature of treatments were not captured, of the 129 patients with NSCLC treated on the phase 1, dose-escalation, cohort expansion trial (CA209-003), 75 (58%) had previously received RT. In the overall patient population of 129 NSCLC cases, there were nine cases of pneumonitis (7.0%) and three cases of grade 3–4 pneumonitis (2.3%), suggesting that the overwhelming majority of NSCLC patients treated with nivolumab after prior RT do not develop pneumonitis. There also is limited experience for patients receiving RT during or after nivolumab therapy. Among approximately 3,000 patients across tumor types (NSCLC, renal cell carcinoma, melanoma) treated with nivolumab to date, approximately 50 were treated with palliative RT during or immediately following nivolumab therapy, with irradiated sites including brain, bone, and lung. No serious adverse events were associated with these cases of palliative RT administration.
In the present trial, enrollment is not restricted to PD-L1 expressors for numerous reasons. Despite early reports suggesting that PD-L1 expressors (≥1%) appear to derive particular benefit from PD-1- and PD-L1-targeted therapies, the definition of PD-L1 expression remains unclear. Furthermore, in preclinical models, RT has been shown to increase tumor expression of PD-L1,\(^9\) which would limit the correlation of outcomes with pre-RT tissue biomarkers. The observation that tumor PD-L1 expression may be prognostic in general lung cancer populations—but not among cases treated with radiation or chemotherapy\(^{20}\)—further suggests that baseline assessment of this biomarker may not adequately define the target population most likely to benefit.

The selection of a cisplatin-etoposide chemotherapy backbone reflects multiple considerations. This regimen has been successfully combined with “consolidation” chemotherapy, such as docetaxel 75 mg/m\(^2\) every 21 days with acceptable toxicity profiles.\(^1\) In a randomized phase 2 trial, the regimen had improved outcomes compared to a carboplatin-paclitaxel-based regimen (3-year OS 33% vs 13%),\(^21\) although survival differences between the regimens have not been noted in population-based observational studies.\(^22,23\) Additionally, cisplatin-etoposide is ideally suited to combination with consolidation nivolumab because, in contrast to carboplatin-paclitaxel chemoradiation regimens, (a) the entire chemotherapy course is administered during the 6 to 7 weeks of thoracic radiation and (b) the steroid requirement (which could hypothetically reduce the efficacy of nivolumab) is lower. Finally, rates of radiation pneumonitis—a toxicity that could hypothetically be exacerbated by immunotherapy—may be lower with concurrent cisplatin-etoposide than with concurrent carboplatin-paclitaxel (approximately 5% versus 15%).\(^1,24\)

There is preclinical evidence supporting the administration of immunotherapy before, during, and after RT. However, administration of immunotherapy before chemoradiation could delay potentially curative treatment for this aggressive disease. Furthermore, clinical considerations support the evaluation of administering nivolumab as consolidation therapy after concurrent chemoradiation. As no chemotherapy will be given with nivolumab, no steroid premedication will be administered, thereby theoretically optimizing immune stimulation. Patients with severe toxicities from concurrent chemoradiation will be identified prior to administration of nivolumab and will have additional time to recuperate from their toxicities. Finally, clinical observations of anti-CTLA-4 antibodies suggest that immunotherapy administration following RT may provide synergistic effects.\(^10\) The initiation of nivolumab 4–12 weeks after completion of chemoradiation reflects previous experience with combined modality regimens for locally advanced disease, prior experience with nivolumab and palliative radiation therapy, and optimization of potential synergistic effects. In concurrent chemoradiation regimens that continue chemotherapy after completion of thoracic radiation, the first post-radiation chemotherapy cycle is commonly given 3–4 weeks after thoracic radiation has ended.\(^1,24\) In the START phase 3 trial of tecemotide (MUC1 vaccine) after chemoradiotherapy, vaccine was initiated 4–12 weeks after chemoradiotherapy completion and was well tolerated.\(^25\) Administration of palliative RT with at least a 14-day window between RT and nivolumab dosing in multiple disease settings has not been associated with increased toxicity. Finally, relatively early initiation of immunotherapy may also capitalize on residual and ongoing radiation-induced tumor antigenic stimulation.\(^5,6\) The administration of nivolumab for up to one year covers the time
period when patients are at greatest risk of recurrence or progression (approximately 75% of cases that eventually progress do so within 12 months\(^{25}\)). Post-treatment fluorodeoxyglucose (FDG) uptake not representing disease recurrence or progression has been reported up to 15 months after completion of chemoradiation.\(^{26}\) If such radiographic findings correspond to physiologic effects related to tumor antigenic stimulation, then this period of time might represent the optimal period to capitalize on the abscopal effect. Prolonged anti-PD-1 therapy also appears tolerable. In nivolumab phase 1 trials, the number of patients who continued nivolumab beyond 6 months (and a smaller number beyond 12 months) due to prolonged radiographic response or stable disease were able to do so without apparent cumulative toxicity.\(^{27}\)

**Objectives**

The co-primary endpoints of this trial are OS (defined as the time from randomization to death due to any cause) and PFS (defined as the time from randomization to documented progressive disease or death due to any cause, whichever occurs first). The PFS co-primary endpoint is based on an independent radiology review committee according to RECIST 1.1.\(^{28}\) PFS was included as a co-primary endpoint because of the possibility of cross-over after progression in the control arm and because some international regulatory bodies incorporate it into consideration for drug label indication. An independent radiology review committee is employed for this endpoint because assessment of disease status post-chemoradiation is notoriously complex (up to 65% of patients have treatment-related radiographic changes\(^{29}\)) and the addition of sequential immunotherapy may further complicate the assessment because of potential “pseudo-progression.”\(^{30}\)

Secondary objectives of this study include the following:

- Compare toxicities in the control and experimental arms
- Compare patient reported outcomes and quality of life (using the Functional Assessment of Cancer Therapy-Trial Outcome Index [FACT-TOI] for lung cancer, the Patient-Reported Outcomes Measurement Information System [PROMIS] fatigue short form, and the EuroQol five dimensions questionnaire [EQ-5D] index and visual analog scale [VAS]) in the control and experimental arms
- Evaluate OS and PFS in (1) PD-L1 expressors (≥1%) and (2) PD-L1 non-expressors (<1%)

Exploratory objectives include the following:

- Evaluate predictive and pharmacodynamic biomarkers
- Determine the proportion of patients alive at 12 and 24 months
- Determine the proportion of patients progression free at 12 and 24 months according to RECIST 1.1
- Compare PFS based on investigator assessment and blinded independent central review
Study Design

This is a multi-center phase 3 randomized, double-blind, placebo-controlled clinical trial sponsored by the RTOG Foundation and Bristol-Myers Squibb. Tumor PD-L1 expression will be determined for all patients but is not required for enrollment. Analysis of PD-L1 expression will be performed by LabCorp by use of the 28–8 antibody to PD-L1 (BMS) using the Dako IHC platform. PD-L1 membrane staining will be assessed by light microscopy. Either complete circumferential or partial linear plasma membrane staining will constitute positive PD-L1 staining.

Figure 1 shows the study schema. All patients will receive concurrent chemoradiation as follows: thoracic radiation therapy (RT) to 60 Gy with concurrent cisplatin 50 mg/m$^2$ IV on Days 1, 8, 29, and 36, and etoposide 50 mg/m$^2$ IV on Days 1–5 and 29–33. Between 4 and 12 weeks after completion of concurrent therapy, eligible patients will be randomized 1:1 to nivolumab 240 mg IV over 30 minutes or placebo every 2 weeks for up to 1 year.

Randomization will be stratified by performance status (ECOG 0 vs 1), histology (squamous vs non-squamous), and tumor PD-L1 expression (≥1%, <1%, not evaluable/undetermined). There are no nivolumab/placebo dose modifications. Depending on toxicities, nivolumab/placebo is given at full dose, withheld, or discontinued. The study requires the use of photons delivered either using 3D-conformal radiation therapy (CRT) or intensity-modulated radiation therapy (IMRT) techniques. Tomotherapy is allowed if appropriately credentialed for its use. Use of stereotactic radiation therapy is not permitted for this trial. The use of image-guided radiation therapy (IGRT) is highly encouraged but not required. Patients are permitted to continue treatment beyond initial RECIST 1.1-defined (PD) as long as the following criteria are met: (a) investigator-assessed clinical benefit and do not have rapid disease progression; (2) tolerance of study drug; (3) stable performance status; (4) treatment beyond progression will not delay an imminent intervention to prevent serious complications of disease progression.

Imaging exams are collected at the following time points: baseline (prior to study treatment); post-chemoradiation; every 3 months for 2 years, every 6 months for years 3–5, then yearly; at disease progression; at request when treatment occurs beyond progression and subsequent tumor evaluations. At the time of investigator-assessed progression, sites request a real-time independent review of progression, which is conducted by a blinded, third party, independent radiologist. If there is discordance between the local and central reviews (ie, central review does not confirm progression), a central adjudicator will review both local and central results to render a final decision on progression. In those cases when the site investigators disagree with final adjudicated central review interpretation, subsequent therapy may be initiated per investigator’s clinical decision, and protocol therapy may be discontinued. Local site investigators also have the option of continuing therapy beyond their local interpretation of progression.

Study Population

Detailed study eligibility criteria are listed in Table 1. Eligible patients have a pathologically (histologically or cytologically) proven diagnosis of stage IIIA or stage IIIB disease (AJCC...
7th edition32) NSCLC with that is unresectable, medically inoperable, or for which resection is refused. Unresectable stage IIIA disease is defined by multiple and/or bulky N2 mediastinal lymph nodes on computed tomography (CT) scan. N2 and/or N3 disease must be documented by biopsy, by fluorodeoxyglucose positron emission tomography (FDG-PET), or by CT (if nodes are more than 2 cm). Core or excisional biopsy is required for this study because fine needle aspirates (FNA) and cytology specimens are not adequate for PD-L1 analysis. Notably, patients are ineligible if they have an active, known, or suspected autoimmune disease.33 Exceptions include vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, and psoriasis not requiring systemic treatment.

**Statistical Analysis Plan**

The study accounts for two primary endpoints: OS and PFS. Overall (2-sided) alpha is 0.05, which is split with 0.01 for evaluating PFS and with 0.04 for evaluating OS. Assuming a rate of 16.7% due to ineligibility and drop-out between initial registration and randomization, a total of 660 patients will be enrolled to ensure 550 patients are randomized after completion of chemoradiation. This sample size will provide ≥90% power to detect a hazard ratio (HR) of 0.667 for PFS with two-sided α=0.01, and 90% power to detect an HR of 0.7 for OS with two-sided α=0.01. The trial will be declared positive if either the OS or PFS comparison of the treatments is statistically significant favoring the experimental arm.

To determine whether the treatment effect is consistent across various subgroups, the estimate of the between-group treatment effect for the primary endpoints will be estimated within each category of the following classification variables: age (≤65, >65 years), sex, race (white, non-white), ECOG status (0, 1), histology (squamous, non-squamous), smoking status (never, former, current).

If the trial is declared positive based on either OS or PFS in the overall intent-to-treat (ITT) population, a step-down procedure will be applied to OS and PFS in the ITT subgroups in the following order: (1) PD-L1 expressors; (2) PD-L1 non-expressors, (3) PD-L1 undetermined, with an overall 2-sided α of 0.05 for each subgroup analysis. In the event that study is not declared positive based on either OS or PFS in the ITT population, the presence of qualitative interactions between PD-L1 status and nivolumab will be assessed by analyzing OS and PFS within each PD-L1 subgroup separately for exploratory purposes. The statistical analysis plan will be same except that no formal hypothesis testing will be performed.

For the QOL secondary endpoint, it is hypothesized that the experimental arm will have a clinically meaningful better QOL due to reduction in disease progression and associated symptoms.

**Effect of This Study**

Recent attempts to improve clinical outcomes in patients with stage 3 NSCLC—including the addition of consolidation chemotherapy, maintenance EGFR inhibitor therapy, sequential vaccine therapy, incorporating trimodality therapy, and increasing radiation dose—have failed. Preclinical models and early clinical experience suggest that locally advanced
NSCLC treated with concurrent chemoradiation may represent the optimal setting for anti-PD1 immune checkpoint inhibitor therapy, which is already approved for previously treated advanced NSCLC. This trial offers unprecedented insight into this therapeutic approach, including not only OS and PFS endpoints, but also patient-reported outcomes, quality of life, and relevant biomarker studies.

Acknowledgments

Funding: Funded in part by the RTOG Foundation, Bristol-Myers Squibb, and a National Cancer Institute (NCI) Midcareer Award in Patient-Oriented Research (K24CA201543-01; to DEG). The authors thank Ms. Dru Gray for assistance with manuscript preparation.

References


Figure 1.
Study schema
* Verification that archived tissue block is available for submission as the completed submission will be required at least 5 weeks prior to Step 2 Registration
** Assessment for progression after chemoRT; if evidence of distant metastases or local disease progression, will not be randomized
Table 1

Trial Eligibility Criteria

<table>
<thead>
<tr>
<th>Step 1—Registration Prior to Chemoradiation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inclusion Criteria</strong></td>
</tr>
<tr>
<td>1. Pathologically (histologically or cytologically) proven diagnosis of NSCLC with unresectable, medically inoperable disease, or patients who refuse resection stage IIIA or stage IIIB disease (AJCC 7th edition)</td>
</tr>
<tr>
<td>2. Age ≥18 years</td>
</tr>
<tr>
<td>3. ECOG Performance Status of 0–1</td>
</tr>
<tr>
<td>4. Adequate hematologic function defined as follows:</td>
</tr>
<tr>
<td>• Absolute neutrophil count (ANC) ≥1,500 cells/mm³</td>
</tr>
<tr>
<td>• Platelets ≥100,000 cells/mm³</td>
</tr>
<tr>
<td>• Hemoglobin ≥9.0 g/dl (Note: The use of transfusion or other intervention to achieve Hgb ≥9.0 g/dl is acceptable.)</td>
</tr>
<tr>
<td>5. Adequate renal function defined as follows:</td>
</tr>
<tr>
<td>Serum creatinine within normal institutional limits or creatinine clearance ≥60 ml/min</td>
</tr>
<tr>
<td>6. Adequate hepatic function defined as follows:</td>
</tr>
<tr>
<td>• Total bilirubin ≤1.5 x institutional upper limit of normal (ULN) (except subjects with Gilbert Syndrome, who can have total bilirubin &lt;3.0 mg/dL)</td>
</tr>
<tr>
<td>• ALT, AST ≤3.0 x institutional ULN</td>
</tr>
<tr>
<td>7. Adequate respiratory function defined as follows:</td>
</tr>
<tr>
<td>FEV1 &gt; 1.2 liters, DLCO ≥50% predicted</td>
</tr>
<tr>
<td>8. Availability of H&amp;E slide and archived tumor block (or two 3mm punches from block) from core or excisional biopsy is required for PD-L1 and other biomarker analysis</td>
</tr>
</tbody>
</table>

| **Exclusion Criteria**                      |
| 1. Definitive clinical or radiologic evidence of metastatic disease |
| 2. Prior or current invasive malignancy (except non-melanomatous skin cancer, localized bladder and prostate cancer) unless disease free for a minimum of 2 years |
| 3. Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields |
| 4. Prior systemic treatment with an anti-PD-1, anti-PD-L1, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways |
| 5. A condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications (inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease) |
| 6. Severe, active co-morbidity defined as follows: |
|   • Active, known or suspected autoimmune disease |
|   • Known immunosuppressive disease (for example HIV infection or history of bone marrow transplant or CLL) |
|   • Chronic Obstructive Pulmonary Disease (COPD) exacerbation or other respiratory illness requiring hospitalization or oral steroid therapy |
|   • Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months |
|   • Transmural myocardial infarction within the last 6 months |
|   • Acute bacterial or fungal infection requiring intravenous antibiotics |
| 7. History of symptomatic or previously established interstitial lung disease |
| 8. Positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection |
| 9. History of severe hypersensitivity reaction to any monoclonal antibody or allergy to study drug components |
| 10. Pregnant, nursing females, or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception |

| Step 2—Registration after completion of chemoradiation, before randomization |
Inclusion Criteria

1. ECOG performance Status of 0 or 1
2. Must be randomized less than 12 weeks following completion of chemoradiotherapy to ensure nivolumab/placebo begins no later than 12 weeks following completion of chemoradiotherapy
3. Laboratory values must meet the following criteria:
   - WBC ≥ 2000/μL
   - Neutrophils ≥ 1000/μL
   - Platelets ≥ 50 x 10^3/μL
   - Hemoglobin > 9.0 g/dL
   - Creatinine ≤ 1.5 x institutional ULN or creatinine clearance (CrCl) ≥ 40 mL/min
   - AST/ALT ≤ 3 x ULN
   - Total Bilirubin ≤ 1.5 x ULN (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL)
4. All toxicities attributed to prior chemoradiation therapy other than alopecia, fatigue, or peripheral neuropathy must have resolved to ≤Grade 2
5. Mandatory submission of H&E slide and block (or two 3mm punches from block) from core or excisional biopsy is required for PD-L1 and other biomarker analysis

Exclusion Criteria

1. Failure to complete minimum required amounts of chemoradiation (defined as at least 50% of intended days of chemotherapy administration and at least 54 Gy total dose of radiation)
2. Bilateral lung V20 > 37% on radiation therapy treatment plan used for concurrent chemoradiotherapy
3. Grade 3 and above pulmonary toxicity of dyspnea, hypoxia, or pneumonitis experienced during chemoradiation
4. Evidence of disease progression after chemoradiation or evidence of metastatic disease